Biocon has reported results for its third quarter ended December 31, 2011.
The company has posted a 69.41% fall in net profit of Rs 64.73 crore for the quarter ended December 31, 2011 as compared to Rs 211.59 crore for the same quarter in the previous year. Total income has decreased by 23.19% from Rs 515.94 crore for Q3FY11 to Rs 396.30 crore in the quarter under review.
On the consolidated basis the group has posted a net profit fall of 15.79% to Rs 84.85 crore for the quarter ended December 31, 2011 as compared to Rs 100.76 crore in the same quarter last year. Total Income of the company improved marginally by 2.65% to Rs 532.18 crore for the quarter compared to Rs 518.44 crore in the quarter, year ago.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.90 |
| Dr. Reddys Lab | 1238.60 |
| Cipla | 1239.40 |
| Zydus Lifesciences | 940.70 |
| Lupin | 2331.30 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: